NGL Fine-Chem (NSE:NGLFINE) EBIT: ₹678 Mil (TTM As of Mar. 2026)


NSE:NGLFINE NGL Fine-Chem Ltd NSE:NGLFINE
78 GF Score
Price ₹2,989.90
GF Value ₹2,803.99
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is NGL Fine-Chem EBIT?

NGL Fine-Chem NSE:NGLFINE -2.72% 78 EBIT is ₹678 Mil as of Mar. 2026. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,803.99 (Fairly Valued). The stock has 8 warning signs investors should review.

NGL Fine-Chem's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹188 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹678 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NGL Fine-Chem's annualized ROC % for the quarter that ended in Mar. 2026 was 11.44%. NGL Fine-Chem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 19.26%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NGL Fine-Chem's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.56%.


NGL Fine-Chem  (NSE:NGLFINE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NGL Fine-Chem's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=654.436 * ( 1 - 24.29% )/( (0 + 4329.46)/ 1 )
=495.4734956/4329.46
=11.44 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5454.958 - 665.27 - ( 460.228 - max(0, 1500.139 - 2763.882+460.228))
=4329.46

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

NGL Fine-Chem's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=752.804/( ( (0 + max(0, 0)) + (2584.455 + max(1324.535, 0)) )/ 1 )
=752.804/( ( 0 + 3908.99 )/ 1 )
=752.804/3908.99
=19.26 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1308.752 + 702.796 + 292.106) - (665.27 + 0 + 313.849)
=1324.535

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NGL Fine-Chem's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=677.5/19009.698
=3.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NGL Fine-Chem EBIT Related Terms


NGL Fine-Chem EBIT Historical Data

* Premium members only.

The historical data trend for NGL Fine-Chem's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NGL Fine-Chem EBIT Chart

NGL Fine-Chem Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 681.58 285.59 557.55 300.48 678.35

NGL Fine-Chem Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.34 130.62 141.24 217.45 188.20

NSE:NGLFINE vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, NGL Fine-Chem's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NGL Fine-Chem EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NGL Fine-Chem's EV-to-EBIT falls into.


NSE:NGLFINE
78GF Score
NGL Fine-Chem Ltd NSE:NGLFINE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NGL Fine-Chem EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹678 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹678 Mil mean?
NGL Fine-Chem (NSE:NGLFINE) has a EBIT of ₹678 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NGL Fine-Chem.
Is NGL Fine-Chem's EBIT too high?
NGL Fine-Chem's current EBIT is ₹678 Mil. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's EBIT compare to LLY and JNJ?
NGL Fine-Chem's EBIT of ₹678 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NGL Fine-Chem. NGL Fine-Chem's current EBIT is ₹678 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,803.99, compared to a current price of ₹2,989.90 — trading 6.6% above its estimated fair value. The current EBIT is ₹678 Mil. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current EBIT is ₹678 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?

Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued. The current stock price of ₹2,989.90 is trading 6.6% above its estimated GF Value™ of ₹2,803.99. GuruFocus considers NGL Fine-Chem to be Fairly Valued.

Key valuation signals for NSE:NGLFINE:

  • EBIT: ₹678 Mil
  • GF Value™: ₹2,803.99 vs. price of ₹2,989.90 (6.6% above fair value)
  • GF Score™: 78/100 with 8 warning signs

No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NGL Fine-Chem Business Description

Other Exchanges 524774:India
Address 301, E Square, Subhash Road, Vile Parle (East), Mumbai, MH, IND, 400057
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score

Get the complete analysis for NSE:NGLFINE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,989.90
Price
₹2,803.99
GF Value